ArticleJournal of aerosol medicine and pulmonary drug delivery2020
Wixela Inhub: Dosing Performance
Article in Journal of aerosol medicine and pulmonary drug delivery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Evaluating 3D-Printed Pre-separator Inserts in a Fast Screening Impactor for Physicochemical Characterization of Fine Particle Dose Release from Dry Powder Inhalers.AAPS PharmSciTech · 2025Article
- Dry-powder inhaler use in primary school-aged children with asthma: a systematic review.ERJ open research · 2024Article
- Comparisons between In-Check DIAL® and PF810® in evaluation and training inspiratory capacity for using dry powder inhalers.BMC pulmonary medicine · 2024Article
- Spatial aerosol deposition correlated to anatomic feature development in 6-year-old upper airway computational models.Computers in biology and medicine · 2022Article
- Article
- Pharmacological Strategies and Recent Advancement in Nano-Drug Delivery for Targeting Asthma.Life (Basel, Switzerland) · 2022Review
- Wixela Inhub: A Generic Equivalent Treatment Option for Patients with Asthma or COPD.Pulmonary therapy · 2021Review
- The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device.Pulmonary medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.